CVI Holdings’s Rein Therapeutics RNTX Stock Holding History

CVI Holdings’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,831	Closed	-$110K	–	77
2019 Q1	$110K	Buy	+2,831	New	+$88.2K	0.1%	35

Other funds holding RNTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

CVI Holdings's RNTX Position: Q2 2019 in Review

CVI Holdings sold out of Rein Therapeutics (RNTX) in Q2 2019, closing a stake of 2,831 shares — an estimated $110K sold.

CVI Holdings first reported a position in RNTX in Q1 2019 and held it in 1 quarter. The position peaked at $110K in Q1 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q2 2019.

CVI Holdings reported no remaining Rein Therapeutics position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 2,831 Rein Therapeutics shares in Q2 2019, an estimated $110K.
CVI Holdings first reported a position in Rein Therapeutics in Q1 2019 and held it in 1 quarter.
CVI Holdings's Rein Therapeutics position peaked at $110K in Q1 2019.
22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.